# Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

> **NCT00321685** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 57 (actual)

## Conditions studied

- Rectal Adenocarcinoma
- Stage II Rectal Cancer AJCC v7
- Stage III Rectal Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin Calcium
- **DRUG:** Oxaliplatin
- **RADIATION:** Radiation Therapy
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT00321685
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-25
- **Primary completion:** 2013-08-12
- **Final completion:** 2019-02-11
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321685, "Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00321685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*